JP6077243B2 - Differentiation inducer from stem cells to ectoderm cells - Google Patents
Differentiation inducer from stem cells to ectoderm cells Download PDFInfo
- Publication number
- JP6077243B2 JP6077243B2 JP2012197729A JP2012197729A JP6077243B2 JP 6077243 B2 JP6077243 B2 JP 6077243B2 JP 2012197729 A JP2012197729 A JP 2012197729A JP 2012197729 A JP2012197729 A JP 2012197729A JP 6077243 B2 JP6077243 B2 JP 6077243B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- differentiation
- black tea
- eye
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004069 differentiation Effects 0.000 title claims description 83
- 210000000130 stem cell Anatomy 0.000 title claims description 59
- 239000000411 inducer Substances 0.000 title claims description 13
- 210000001705 ectoderm cell Anatomy 0.000 title description 33
- 210000004027 cell Anatomy 0.000 claims description 142
- 244000269722 Thea sinensis Species 0.000 claims description 81
- 235000020279 black tea Nutrition 0.000 claims description 71
- 235000006468 Thea sinensis Nutrition 0.000 claims description 70
- 239000000284 extract Substances 0.000 claims description 59
- 230000001939 inductive effect Effects 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 14
- 210000000695 crystalline len Anatomy 0.000 claims description 14
- 210000001525 retina Anatomy 0.000 claims description 14
- 239000000470 constituent Substances 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 208000030533 eye disease Diseases 0.000 claims description 9
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 7
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 210000003560 epithelium corneal Anatomy 0.000 claims description 3
- 210000000554 iris Anatomy 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 1
- 230000006698 induction Effects 0.000 description 34
- 238000000605 extraction Methods 0.000 description 29
- 239000003550 marker Substances 0.000 description 29
- 239000002609 medium Substances 0.000 description 26
- 210000002569 neuron Anatomy 0.000 description 26
- 239000003814 drug Substances 0.000 description 18
- 239000002771 cell marker Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 101100295848 Drosophila melanogaster Optix gene Proteins 0.000 description 13
- 101150092239 OTX2 gene Proteins 0.000 description 13
- 108700010572 Sine oculis homeobox homolog 3 Proteins 0.000 description 13
- 230000024245 cell differentiation Effects 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 210000003981 ectoderm Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000004129 prosencephalon Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- -1 etc. may be added Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 235000013616 tea Nutrition 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000003889 eye drop Substances 0.000 description 8
- 210000003061 neural cell Anatomy 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 229940012356 eye drops Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000001172 regenerating effect Effects 0.000 description 6
- 210000000697 sensory organ Anatomy 0.000 description 6
- 208000020431 spinal cord injury Diseases 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 5
- 101150081664 PAX6 gene Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 229960004857 mitomycin Drugs 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000001988 somatic stem cell Anatomy 0.000 description 5
- 210000002536 stromal cell Anatomy 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 210000002242 embryoid body Anatomy 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 3
- 108010049048 Cholera Toxin Proteins 0.000 description 3
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000007055 Endothelin-3 Human genes 0.000 description 3
- 108010072844 Endothelin-3 Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- ZGOVYTPSWMLYOF-QEADGSHQSA-N chembl1790180 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@H](CCC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)[C@H](C)O)=O)NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZGOVYTPSWMLYOF-QEADGSHQSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004031 neuronal differentiation Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 235000020339 pu-erh tea Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000004264 retinal detachment Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- CETWDUZRCINIHU-UHFFFAOYSA-N 2-heptanol Chemical compound CCCCCC(C)O CETWDUZRCINIHU-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 101150009249 MAP2 gene Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000005155 neural progenitor cell Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000023895 stem cell maintenance Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007766 Cataract traumatic Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 206010051181 Nasal odour Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 206010033712 Papilloedema Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- KDKJYYNXYAZPIK-UHFFFAOYSA-J aluminum potassium disulfate hydrate Chemical compound O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O KDKJYYNXYAZPIK-UHFFFAOYSA-J 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本発明は、幹細胞から外胚葉系細胞への分化誘導剤、該分化誘導剤を含む医薬品、医薬部外品、および飲食品、ならびに外胚葉系細胞の製造方法に関する。 The present invention relates to a differentiation-inducing agent from stem cells to ectoderm cells, pharmaceuticals containing the differentiation-inducing agents, quasi-drugs, foods and drinks, and methods for producing ectoderm cells.
幹細胞は、様々な細胞に分化できる多分化能と、細胞分裂を経ても多分化能(未分化状態)を維持できる自己増殖能とを併せ持つ細胞である。なかでも、体性幹細胞は、生体内の各組織に存在しており、障害若しくは疾患または老化等に伴って組織の細胞が失われた場合に、新たな細胞を供給することにより組織の恒常性を維持している。また、ES細胞(胚性幹細胞)やiPS細胞(人工多能性幹細胞)などの多能性幹細胞は、人工的につくり出された幹細胞であり、生体を構成する全ての細胞種に分化できる能力(多能性)と無限増殖性を有している。 A stem cell is a cell having both multipotency capable of differentiating into various cells and self-proliferation ability capable of maintaining multipotency (undifferentiated state) even after cell division. Among them, somatic stem cells exist in each tissue in the living body, and when the cells of the tissue are lost due to a disorder or disease or aging, the tissue homeostasis is supplied by supplying new cells. Is maintained. In addition, pluripotent stem cells such as ES cells (embryonic stem cells) and iPS cells (artificial pluripotent stem cells) are artificially created stem cells that have the ability to differentiate into all cell types that make up the body. (Multipotency) and unlimited proliferation.
近年、再生医療をはじめとする先端医療の分野において、これらの幹細胞の性質を臓器や組織の再生に応用する活発な研究が進められている(非特許文献1)。例えば、哺乳類の眼、特に網膜はいったん障害を受けると自然には再生しない。このため、網膜色素変性症などの網膜変性症には治療法がなく、失明に至ることから、幹細胞を利用した再生医療が期待されている。このような背景の中、近年の幹細胞技術の進歩により、マウスやヒトのES細胞やiPS細胞から網膜(網膜色素上皮、神経網膜)や水晶体等の眼組織・細胞を誘導することが可能となっており、将来的にはこれらの誘導された眼組織・細胞の移植により従来有効な治療法がなかった眼疾患の治療が可能となることが期待されている(非特許文献2、3)。 In recent years, in the field of advanced medicine including regenerative medicine, active researches are being carried out to apply the properties of these stem cells to regeneration of organs and tissues (Non-patent Document 1). For example, the mammalian eye, especially the retina, does not regenerate naturally once damaged. For this reason, there is no cure for retinal degeneration such as retinitis pigmentosa, leading to blindness, and regenerative medicine using stem cells is expected. Against this background, recent advances in stem cell technology have made it possible to induce eye tissues / cells such as the retina (retinal pigment epithelium, nerve retina) and lens from mouse and human ES cells and iPS cells. In the future, it is expected that transplantation of these induced ocular tissues / cells will enable treatment of eye diseases for which there has been no effective therapeutic method (Non-Patent Documents 2 and 3).
また、日本には約10万人の脊髄損傷患者が存在し、毎年新たに約5000人の受傷者が生じていると言われている。重症の場合には手足がほとんど動かず、寝たきりや車椅子の生活を余儀なくされている。現在のところ、脊髄損傷によって失われた機能を回復するために有効な治療法は確立されていない。その理由としては、中枢神経系では損傷後の神経再生が非常に起こりにくいことが挙げられる。このため、脊髄損傷にもやはり幹細胞による再生医療が期待されており、すでに幹細胞から中枢神経系への様々な分化誘導技術が確立されている(非特許文献4)。一方で、上記幹細胞を利用した再生医療を現実なものとするためには、幹細胞から効率的に目的細胞への分化を制御する物質や技術の開発が必須である。 In Japan, there are about 100,000 people with spinal cord injury, and it is said that about 5,000 people are injured every year. In severe cases, the limbs hardly move, and people are forced to live on a bedridden or wheelchair. At present, no effective treatment has been established to restore the function lost by spinal cord injury. The reason for this is that nerve regeneration after injury is very unlikely in the central nervous system. For this reason, regenerative medicine using stem cells is also expected for spinal cord injury, and various differentiation induction techniques from stem cells to the central nervous system have already been established (Non-Patent Document 4). On the other hand, in order to make regenerative medicine using the stem cells a reality, it is essential to develop substances and techniques that efficiently control the differentiation of stem cells into target cells.
脊椎動物の初期胚の発生過程では胚葉形成と呼ばれる細胞の系統分化が起き、外胚葉、中胚葉、内胚葉の三種類の細胞集団が形成される。このうち、外胚葉は神経系細胞、感覚系細胞、表皮を生み出す。よって、幹細胞から外胚葉、さらには、外胚葉を由来とする細胞や組織を分化誘導することができれば、上記の眼疾患や脊髄損傷の治療への可能性が広がる。 In the development process of vertebrate early embryos, cell lineage differentiation called germ layer formation occurs, and three types of cell populations are formed: ectoderm, mesoderm, and endoderm. Of these, the ectoderm produces nervous system cells, sensory system cells, and epidermis. Therefore, if differentiation and induction of ectoderm, and further cells and tissues derived from ectoderm from stem cells, the possibilities for the treatment of the above eye diseases and spinal cord injury are expanded.
一方、中国で一般的に飲まれている「黒茶」は、微生物発酵茶で、その代表であるプーアール茶は、脂肪吸収抑制作用などの効能が知られている。また、黒茶の抽出物には血糖値上昇抑制作用があることが報告されるが(特許文献1)、未分化な幹細胞に及ぼす影響についてはこれまで何ら検討されていない。 On the other hand, “black tea” commonly drunk in China is a microbial fermented tea, and its typical pu-erh tea is known to have effects such as fat absorption inhibition. Moreover, although it is reported that the extract of black tea has a blood glucose level raise inhibitory effect (patent document 1), the influence on an undifferentiated stem cell is not examined at all until now.
本発明の目的は、幹細胞から外胚葉系細胞への分化誘導活性を有する物質を見出し、これまで治療が困難であった眼疾患や神経疾患を根本的に予防、改善または治療するための医薬品や飲食品などの組成物を提供することにある。 An object of the present invention is to find a substance having an activity of inducing differentiation from stem cells to ectoderm cells, and to provide a drug for fundamentally preventing, improving or treating eye diseases and neurological diseases that have been difficult to treat so far. It is in providing compositions, such as food-drinks.
本発明者らは、上記課題を解決すべく鋭意研究を重ねた結果、黒茶抽出物を幹細胞の培養系に添加することにより、幹細胞において外胚葉系細胞特異的マーカー遺伝子の発現が亢進することを見出すとともに、神経細胞又は眼様構造体への分化が促進されることを確認し、本発明を完成させるに至った。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have increased expression of ectodermal cell-specific marker genes in stem cells by adding black tea extract to the stem cell culture system. As a result, it was confirmed that differentiation into nerve cells or eye-like structures was promoted, and the present invention was completed.
すなわち、本発明は以下の発明を包含する。
(1) 黒茶抽出物を有効成分として含有する、幹細胞から外胚葉系細胞への分化誘導剤。
(2) 外胚葉系細胞が感覚器系細胞または神経系細胞である、(1)に記載の分化誘導剤。
(3) 感覚器系細胞が眼の構成細胞である、(2)に記載の分化誘導剤。
(4) 眼の構成細胞が、網膜、水晶体、角膜上皮、または虹彩の細胞である、(3)に記載の分化誘導剤。
(5) (1)〜(4)のいずれかに記載の分化誘導剤を含む、医薬品または飲食品。
(6) 眼疾患または神経疾患の治療または予防のための(5)に記載の医薬品または飲食品。
(7) 黒茶抽出物の存在下で幹細胞を培養して外胚葉系細胞へ分化誘導することを特徴とする、幹細胞から外胚葉系細胞への分化誘導方法。
(8) 黒茶抽出物の存在下で幹細胞を培養して外胚葉系細胞へ分化誘導する工程を含む、外胚葉系細胞の製造方法。
(9) (8)に記載の方法により製造された外胚葉系細胞。
That is, the present invention includes the following inventions.
(1) An agent for inducing differentiation from stem cells to ectoderm cells, containing black tea extract as an active ingredient.
(2) The differentiation inducer according to (1), wherein the ectoderm cells are sensory organ cells or nervous cells.
(3) The differentiation inducer according to (2), wherein the sensory organ cells are constituent cells of the eye.
(4) The differentiation inducer according to (3), wherein the eye constituent cells are retina, lens, corneal epithelium, or iris cells.
(5) A pharmaceutical product or food or drink comprising the differentiation inducer according to any one of (1) to (4).
(6) The pharmaceutical product or food or drink according to (5) for the treatment or prevention of eye diseases or neurological diseases.
(7) A method for inducing differentiation from stem cells to ectoderm cells, comprising culturing stem cells in the presence of black tea extract to induce differentiation into ectoderm cells.
(8) A method for producing ectoderm cells, comprising a step of culturing stem cells in the presence of black tea extract to induce differentiation into ectoderm cells.
(9) An ectoderm cell produced by the method according to (8).
本発明によれば、幹細胞から外胚葉系細胞への分化誘導剤が提供される。本発明の分化誘導剤は、幹細胞から外胚葉系細胞、例えば水晶体や網膜などの眼の構成細胞、神経細胞への分化を誘導することができるので、白内障、緑内障、網膜剥離及びその他の眼疾患や脊髄損傷等の神経障害を根本的に予防、改善または治療するための医薬品や飲食品として利用できる。また、本発明の分化誘導剤を用いて幹細胞から分化誘導することにより作製された外胚葉系細胞は、眼や神経の損傷部位に移植してその機能を回復させる再生医療への応用が可能となる。さらに、本発明の分化誘導剤は、水晶体及び網膜などの眼の構成細胞や神経細胞の分化の基礎研究用試薬としても利用できる。 According to the present invention, an agent for inducing differentiation from stem cells to ectoderm cells is provided. The differentiation-inducing agent of the present invention can induce differentiation from stem cells to ectodermal cells, for example, eye constituent cells such as the lens and retina, and nerve cells, so that cataracts, glaucoma, retinal detachment and other eye diseases It can be used as a pharmaceutical or food or drink for fundamentally preventing, improving or treating neurological disorders such as spinal cord injury. In addition, ectoderm cells produced by inducing differentiation from stem cells using the differentiation inducer of the present invention can be applied to regenerative medicine in which the function is restored by transplantation to the damaged site of the eye or nerve. Become. Furthermore, the differentiation-inducing agent of the present invention can be used as a reagent for basic research on differentiation of eye constituent cells such as lens and retina and nerve cells.
以下に、本発明について詳細に述べる。
本発明の幹細胞から外胚葉系細胞への分化を誘導する分化誘導剤(以下、「外胚葉系細胞分化誘導剤」と称する場合がある)は、黒茶抽出物を有効成分とする。
The present invention will be described in detail below.
The differentiation inducer for inducing differentiation from stem cells to ectoderm cells of the present invention (hereinafter sometimes referred to as “ectodermal cell differentiation inducer”) contains black tea extract as an active ingredient.
本発明における「幹細胞から外胚葉系細胞への分化誘導」とは、生体レベルでまたは培養レベルで幹細胞から外胚葉系細胞の分化を誘導及び促進し、外胚葉系細胞を増加させることをいう。 In the present invention, “differentiation induction from stem cells to ectoderm cells” refers to inducing and promoting the differentiation of ectoderm cells from stem cells at a living body level or a culture level to increase ectoderm cells.
本発明において「幹細胞」とは、外胚葉系細胞に分化しうる各種の幹細胞をいい、胚性幹細胞(ES細胞)、骨髄、皮膚、皮下脂肪、脳、網膜、鼻臭球等、その他の組織に存在する未分化な状態の細胞(総称して、体性幹細胞という)、人工多能性幹細胞(iPS細胞)などを含む。ES細胞としては、例えば、着床以前の初期胚を培養することによって樹立されたES細胞、体細胞の核を核移植することによって作製された初期胚を培養することによって樹立されたES細胞、及びそれらのES細胞の染色体上の遺伝子を遺伝子工学の手法を用いて改変したES細胞が挙げられる。このようなES細胞は、例えば、自体公知の方法によって作製することができるが、所定の機関より入手でき、さらには市販品を購入することもできる。また、これら幹細胞は、初代培養細胞、継代培養細胞、凍結細胞のいずれであってもよい。 In the present invention, “stem cells” refer to various stem cells that can differentiate into ectoderm cells, embryonic stem cells (ES cells), bone marrow, skin, subcutaneous fat, brain, retina, nasal odor bulb, and other tissues. And undifferentiated cells (collectively referred to as somatic stem cells), induced pluripotent stem cells (iPS cells), and the like. Examples of ES cells include ES cells established by culturing early embryos before implantation, ES cells established by culturing early embryos produced by nuclear transfer of somatic cell nuclei, And ES cells obtained by modifying genes on the chromosomes of those ES cells using genetic engineering techniques. Such ES cells can be prepared, for example, by a method known per se, but can be obtained from a predetermined institution, and further commercially available products can be purchased. In addition, these stem cells may be primary cultured cells, subcultured cells, or frozen cells.
また、本発明の外胚葉系細胞への分化誘導剤は、幹細胞の分化の方向性、および、分化の過程等について同等の特性を持っていれば、全ての哺乳動物に応用が可能である。例えば、ヒト、サル、マウス、ラット、モルモット、ハムスター、ウサギ、ネコ、イヌ、ウマ、ウシ、ヒツジ、ヤギ、ブタ等の哺乳動物の幹細胞に対して効果を発揮することができる。 Further, the agent for inducing differentiation into ectoderm cells of the present invention can be applied to all mammals as long as they have equivalent characteristics regarding the direction of differentiation of stem cells and the process of differentiation. For example, the effect can be exerted on stem cells of mammals such as human, monkey, mouse, rat, guinea pig, hamster, rabbit, cat, dog, horse, cow, sheep, goat and pig.
外胚葉は、主に表層外胚葉と神経外胚葉に分けられるが、本発明において、「外胚葉系細胞」とは、表層外胚葉性細胞と神経外胚葉性細胞の両者をいい、初期胚の細胞やES細胞などの多能性細胞から分化の初期段階で形成される外胚葉細胞(神経や皮膚の共通前駆細胞)、さらには外胚葉から分化・発生する神経や感覚器を構成する細胞、皮膚の細胞等の両方を含む概念である。外胚葉由来の細胞としては、感覚器系細胞(網膜や内耳の細胞)、神経系細胞(神経幹細胞、神経細胞(例えば、前脳神経細胞、中脳神経細胞、小脳神経細胞、後脳神経細胞、脊髄神経細胞等)、神経管細胞、神経堤細胞)、表皮系細胞(表皮細胞、水晶体上皮細胞)などが挙げられる。 The ectoderm is mainly divided into superficial ectoderm and neuroectoderm. In the present invention, “ectodermal cell” refers to both superficial ectoderm cells and neuroectodermal cells. Ectodermal cells formed in the early stages of differentiation from pluripotent cells such as cells and ES cells (common precursor cells of nerves and skin), and cells that make up nerves and sensory organs that differentiate and develop from ectoderm, It is a concept that includes both skin cells and the like. The ectoderm-derived cells include sensory organ cells (retina and inner ear cells), nervous system cells (neural stem cells, neurons (eg, forebrain neurons, midbrain neurons, cerebellar neurons, hindbrain neurons, spinal nerves). Cells), neural tube cells, neural crest cells), epidermal cells (epidermal cells, lens epithelial cells) and the like.
本発明により分化誘導された細胞が、上記の外胚葉系細胞であるか否かは、例えば、各種の神経系細胞マーカーや感覚器系細胞マーカーの発現により確認できる。本発明において用いることのできる神経系細胞マーカーや感覚器系細胞マーカーとしては、例えば、Otx2(外胚葉・神経細胞・眼の分化マーカー: W02005/123902、Nature. 1992 Aug 20;358(6388):687-90. Nested expression domains of four homeobox genes in developing rostral brain. Simeone A, Acampora D, Gulisano M, Stornaiuolo A, Boncinelli E. SourceInternational Institute of Genetics and Biophysics, CNR, Naples, Italy.)、Sox1(神経細胞・眼の分化マーカー: W02005/123902)、Six3(前脳領域・眼の分化マーカー:Cereb Cortex. 2008 Mar;18(3):553-62. Epub 2007 Jun 18. Six3 controls the neural progenitor status in the murine CNS. Appolloni I, Calzolari F, Corte G, Perris R, Malatesta P.)、Pax6(神経前駆細胞、眼の分化マーカー: W02005/123902)、Tuj-1(神経細胞マーカー: Mod Pathol. 2007 Jul;20(7):742-8. Epub 2007 Apr 27. Expression of Sox2 in mature and immature teratomas of central nervous system. Phi JH, Park SH, Paek SH, Kim SK, Lee YJ, Park CK, Cho BK, Lee DH, Wang KC.)、Map2(成熟神経細胞マーカー: W02005/123902、J Neurosci Res. 2002 Nov 1; 70(3):327-34. Expression patterns of immature neuronal markers PSA-NCAM, CRMP-4 and NeuroD in the hippocampus of young adult and aged rodents. Seki T.)、Crystalin(水晶体マーカー)などが挙げられる。 Whether or not the cells induced to differentiate according to the present invention are the above-mentioned ectoderm cells can be confirmed by, for example, expression of various neural cell markers and sensory organ cell markers. Examples of neuronal cell markers and sensory organ cell markers that can be used in the present invention include Otx2 (ectodermal / neural cell / eye differentiation marker: W02005 / 123902, Nature. 1992 Aug 20; 358 (6388): 687-90. Nested expression domains of four homeobox genes in developing rostral brain.Simeone A, Acampora D, Gulisano M, Stornaiuolo A, Boncinelli E. SourceInternational Institute of Genetics and Biophysics, CNR, Naples, Italy.), Sox1・ Eye differentiation marker: W02005 / 123902), Six3 (Forebrain region / Eye differentiation marker: Cereb Cortex. 2008 Mar; 18 (3): 553-62. Epub 2007 Jun 18. Six3 controls the neural progenitor status in the murine CNS. Appolloni I, Calzolari F, Corte G, Perris R, Malatesta P.), Pax6 (neural progenitor cells, ocular differentiation marker: W02005 / 123902), Tuj-1 (neural cell marker: Mod Pathol. 2007 Jul; 20 (7): 742-8. Epub 2007 Apr 27. Expression of Sox2 in mature and immature teratomas of central nervous system. Phi JH, Park SH, Paek SH, Kim SK, Lee YJ, Park CK, Cho BK, Lee DH, Wang KC.), Map2 (mature neuron marker: W02005 / 123902, J Neurosci Res. 2002 Nov 1; 70 (3 ): 327-34. Expression patterns of immature neuronal markers PSA-NCAM, CRMP-4 and NeuroD in the hippocampus of young adult and aged rodents. Seki T.), Crystalin (lens marker) and the like.
本発明に用いる「黒茶」とは、茶(学名:カメリアシネンシス)の葉を加熱した後、黒麹菌等の微生物により発酵させ、乾燥させた茶をいう。黒茶は、製法上「後発酵茶」に分類され、通常の茶葉形態の「散茶」のほか、茶葉を堆積して後発酵を進行させた後に薄板状等に圧し固めた「磚茶」がある。黒茶は、広く中国で飲用されており、例えば、産地の違いにより「プーアール茶」、「六堡茶」、「黒磚茶」、「茯磚茶」、「康磚茶」などがある。日本でも黒茶は少量ではあるが製造されており、高知県の「碁石茶」、徳島県の「阿波番茶」、富山県の「バタバタ茶」などが知られている。本発明で用いる黒茶は、微生物で後発酵させたものであればいずれも使用可能であり、上記に示したいずれの黒茶を用いてよいが、入手の容易さや効果の面からバタバタ茶やプーアール茶が好ましい。 The “black tea” used in the present invention refers to tea obtained by heating leaves of tea (scientific name: Camellia sinensis), fermenting them with microorganisms such as black koji molds, and drying them. Black tea is classified as “post-fermented tea” due to its manufacturing method. In addition to the “tea powder” in the form of the normal tea leaves, “tea tea” that has been pressed into a thin plate shape after the tea leaves have been deposited and post-fermentation has been advanced is there. Black tea is widely drunk in China and includes, for example, “pu-erh tea”, “six tea tea”, “black tea tea”, “tea tea”, and “kang tea” depending on the production area. Even in Japan, black tea is produced in small quantities, and is known as Kozuku's “Soseki Tea”, Tokushima's “Awabancha”, Toyama's “Batabata Tea” and so on. Any black tea used in the present invention can be used as long as it is post-fermented with microorganisms, and any of the black teas shown above may be used, but from the viewpoint of availability and effects, Pu-erh tea is preferred.
本発明の有効成分である「黒茶抽出物」は、黒茶の葉から溶媒で抽出することにより得られる。抽出に用いる溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1-プロパノール、2-プロパノール、1-ブタノール、2-ブタノール、1-ヘプタノール、2-ヘプタノール等)、液状多価アルコール類(プロピレングリコール、グリセリン、1,3-ブチレングリコール等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、プロピルエーテル、テトラヒドロフラン等)が挙げられる。好ましくは、水、低級アルコール類、液状多価アルコール等の極性溶媒であり、より好ましくは、水、エタノール、プロピレングリコール、1,3-ブチレングリコールである。これらの溶媒は一種でも二種以上を混合して用いても良い。 The “black tea extract” which is an active ingredient of the present invention can be obtained by extracting from black tea leaves with a solvent. Examples of the solvent used for extraction include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 1-heptanol, 2-heptanol, etc.), liquid polyhydric alcohols (Propylene glycol, glycerin, 1,3-butylene glycol, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), And ethers (ethyl ether, propyl ether, tetrahydrofuran, etc.). Preferred are polar solvents such as water, lower alcohols, and liquid polyhydric alcohols, and more preferred are water, ethanol, propylene glycol, and 1,3-butylene glycol. These solvents may be used alone or in combination of two or more.
抽出に使用する溶媒量は、抽出原料1重量部に対して通常2〜200重量部、好ましくは10〜100重量部である。抽出溶媒量がこの範囲を下回ると、抽出原料全体に抽出溶媒が行き渡らず、抽出効率が低下する可能性があり、抽出溶媒量がこの範囲を超えると、後に抽出溶媒除去を行う際の負担が増加する。 The amount of solvent used for extraction is usually 2 to 200 parts by weight, preferably 10 to 100 parts by weight, per 1 part by weight of the extraction raw material. If the amount of the extraction solvent falls below this range, the extraction solvent does not reach the entire extraction raw material, and the extraction efficiency may decrease.If the amount of the extraction solvent exceeds this range, the burden of removing the extraction solvent later will be reduced. To increase.
抽出温度は、抽出に使用する溶媒の沸点以下の温度であり、特に限定されず、例えば加熱抽出であってもよいし、常温抽出であってもよい。 The extraction temperature is a temperature not higher than the boiling point of the solvent used for extraction, and is not particularly limited. For example, it may be heat extraction or room temperature extraction.
抽出時間は、常温抽出の場合は3〜10日間、加熱抽出の場合は30分間〜24時間、好ましくは1〜10時間であるが、抽出溶媒の種類、抽出温度等の条件によって適宜調節できる。抽出操作の回数は特に限定されるものではなく、1回であってもよいし、1回目の抽出後に再度新鮮な抽出溶媒を添加し、2回目以降の抽出操作を行なってもよい。また、同一の抽出溶媒を用いて複数回抽出操作を行ってもよい。 The extraction time is 3 to 10 days for normal temperature extraction and 30 minutes to 24 hours, preferably 1 to 10 hours for heat extraction, but can be appropriately adjusted depending on conditions such as the type of extraction solvent and extraction temperature. The number of extraction operations is not particularly limited, and may be one, or a fresh extraction solvent may be added again after the first extraction, and the second and subsequent extraction operations may be performed. Moreover, you may perform extraction operation in multiple times using the same extraction solvent.
抽出方法は、当分野で通常用いられる方法であればよく、室温又は加熱下で、任意の装置を使用して行う。具体的には、抽出溶媒を満たした抽出処理槽に抽出原料を投入し、必要に応じて時々攪拌しながら可溶性成分を溶出した後、濾過して残渣を除去し、抽出物を得る。 The extraction method may be any method commonly used in the art, and is performed using an arbitrary apparatus at room temperature or under heating. Specifically, an extraction raw material is put into an extraction processing tank filled with an extraction solvent, and a soluble component is eluted with occasional stirring as necessary, followed by filtration to remove a residue to obtain an extract.
上記抽出物は、抽出した溶液のまま用いてもよく、必要に応じて、その効果に影響のない範囲で更に、濃縮、希釈、濾過、活性炭等による脱色、脱臭、エタノール沈殿等の処理をして用いてもよい。さらには、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いてもよい。 The above extract may be used as it is, and if necessary, it may be further treated for concentration, dilution, filtration, decolorization with activated carbon, deodorization, ethanol precipitation, etc. within the range that does not affect the effect. May be used. Further, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product.
上記のようにして得られた黒茶抽出物は、幹細胞から外胚葉系細胞への分化を培養レベルまたは生体レベルで誘導する作用を有する。従って、本発明の外胚葉系細胞分化誘導剤は、その有効量を添加した幹細胞分化誘導培地にて幹細胞を培養することによって、または、ヒトを含む哺乳動物に投与することによって、幹細胞から外胚葉系細胞への分化を誘導することができる。 The black tea extract obtained as described above has an action of inducing differentiation from stem cells to ectoderm cells at the culture level or the living body level. Therefore, the ectodermal cell differentiation inducing agent of the present invention can be obtained by culturing stem cells in a stem cell differentiation induction medium to which an effective amount thereof is added, or by administering them to mammals including humans. Differentiation into lineage cells can be induced.
幹細胞から外胚葉系細胞への分化誘導を幹細胞の培養により行う場合、培地に上記外胚葉系細胞分化誘導剤を添加する以外は、培養方法の条件及び操作は、当該技術分野で常套的な条件及び操作に従って行うことができる。外胚葉系細胞分化誘導剤の培地への添加量は、黒茶抽出物濃度として1〜1000μg/mL、好ましくは10〜100μg/mLである。 When differentiation induction from stem cells to ectoderm cells is performed by culturing stem cells, the conditions and operations of the culture method are the conditions that are conventional in the art, except that the ectoderm cell differentiation inducer is added to the medium. And according to the operation. The addition amount of the ectodermal cell differentiation inducer to the medium is 1-1000 μg / mL, preferably 10-100 μg / mL, as the concentration of black tea extract.
幹細胞の培養には、幹細胞の維持または分化誘導の目的に適する組成の培地を使用する。幹細胞分化誘導培地としては、具体的には、細胞の生存増殖に必要な成分(無機塩、炭水化物、ホルモン、必須アミノ酸、非必須アミノ酸、ビタミン)を含む基本培地(例えば、Dulbecco's modified Eagle's medium(D-MEM)、Minimum Essential Medium (MEM)、RPMI1640、Basal Medium Eagle (BME)、Dulbecco's modified Eagle's medium:Nutrient Mixture F-12 (D-MEM/F-12)、Glasgow Minimum Essential Meidum (Glasgow MEM)、ハンクス液(Hank's balanced salt solution)、MCDB153培地)に、basic Fibroblast Growth Factor (bFGF)、Epidermal Growth Factor(EGF)などの増殖因子を少なくとも1種添加した培地が用いられる。また、当該培地には、細胞の増殖速度を増大させるために、必要に応じて、Tumor Necrosis Factor(TNF)、ビタミン類、インターロイキン類、インスリン、トランスフェリン、ヘパリン、ヘパラン硫酸、コラーゲン、ウシ血清アルブミン(BSA)、フィブロネクチン、プロゲステロン、セレナイト、B27-サプリメント、N2-サプリメント、ITS-サプリメントなどを添加してもよく、また抗生物質を添加してもよい。培地の各成分は、各々適する方法で滅菌して使用する。 For the culture of stem cells, a medium having a composition suitable for the purpose of stem cell maintenance or differentiation induction is used. Specifically, the stem cell differentiation-inducing medium includes a basic medium (for example, Dulbecco's modified Eagle's medium (D) containing components (inorganic salts, carbohydrates, hormones, essential amino acids, non-essential amino acids, vitamins) necessary for cell survival and proliferation. -MEM), Minimum Essential Medium (MEM), RPMI1640, Basal Medium Eagle (BME), Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (D-MEM / F-12), Glasgow Minimum Essential Meidum (Glasgow MEM), Hanks A medium in which at least one kind of growth factor such as basic Fibroblast Growth Factor (bFGF) or Epidermal Growth Factor (EGF) is added to the liquid (Hank's balanced salt solution) or MCDB153 medium is used. The medium also contains Tumor Necrosis Factor (TNF), vitamins, interleukins, insulin, transferrin, heparin, heparan sulfate, collagen, bovine serum albumin as necessary to increase the cell growth rate. (BSA), fibronectin, progesterone, selenite, B27-supplement, N2-supplement, ITS-supplement, etc. may be added, and antibiotics may be added. Each component of the medium is used after being sterilized by a suitable method.
また、上記以外には、1〜20%の含有率で血清が含まれることが好ましい。しかし、血清はロットの違いにより成分が異なり、その効果にバラツキがあるため、ロットチェックを行った後に使用することが好ましい。 In addition to the above, serum is preferably contained at a content of 1 to 20%. However, since serum has different components depending on the lot and there are variations in the effects, it is preferable to use the serum after a lot check.
幹細胞の培養は、未分化状態を保つために、Mitomycin C(MMC)処理したMouse Embryonic Fibroblast(MEF)などをフィーダー細胞として用い、幹細胞維持用培地(基本培地にLeukemia Inhibitory Factor(LIF)、L-グルタミン酸等を添加した培地)にて行い、また、幹細胞の外胚葉系細胞への分化誘導は、未分化状態を維持し培養した幹細胞を、改めて別のフィーダー細胞上に播種し、分化を促すような種々の因子を加えて培養することにより行う。フィーダー細胞としては、特に限定されないがマウスストローマ細胞であるST2細胞やPA6細胞が好ましい。分化を促すような種々の因子としては、Dexamethasone(DEX)、bFGF、Cholera Toxin(CT)、Endothelin-3(EDN3)が挙げられるが特に限定されるものではない。 In order to maintain the undifferentiated state of stem cells, Mouse Embryonic Fibroblast (MEF) treated with Mitomycin C (MMC) is used as a feeder cell, and a stem cell maintenance medium (Leukemia Inhibitory Factor (LIF), L- Induction of differentiation of stem cells into ectoderm cells is performed by seeding the cultured stem cells in an undifferentiated state on another feeder cell to promote differentiation. It is performed by adding various other factors and culturing. The feeder cells are not particularly limited, but ST2 cells and PA6 cells which are mouse stromal cells are preferable. Examples of various factors that promote differentiation include, but are not limited to, dexamethasone (DEX), bFGF, Cholera Toxin (CT), and Endothelin-3 (EDN3).
幹細胞の培養または幹細胞に分化を促す場合の容器としては、使い捨てのシャーレを使用することが好ましい。なお、培地の交換は2〜3日に1回行うことが好ましいが、より好ましくは毎日行うことが好ましい。また、幹細胞から角膜や水晶体(レンズ)及び網膜を含む眼組織への分化誘導は12日以上行うのが好ましい。 A disposable petri dish is preferably used as a container for culturing stem cells or promoting differentiation into stem cells. In addition, although it is preferable to perform culture medium exchange once every 2 to 3 days, it is more preferable to carry out daily. In addition, differentiation induction from stem cells to eye tissues including the cornea, lens (lens) and retina is preferably performed for 12 days or more.
一方、本発明の外胚葉系細胞分化誘導剤を生体内に投与する場合は、そのまま投与することも可能であるが、本発明の効果を損なわない範囲で適当な添加物とともに医薬品、医薬部外品、飲食品などの組成物に配合することができる。 On the other hand, when the ectodermal cell differentiation inducer of the present invention is administered in vivo, it can be administered as it is, but within the range not impairing the effects of the present invention, along with appropriate additives, pharmaceuticals and quasi drugs. It can mix | blend with compositions, such as goods and food-drinks.
本発明の外胚葉系細胞分化誘導剤を医薬品として提供する場合は、黒茶抽出物に、医薬上許容され、かつ剤型に応じて適宜選択した製剤用基材や担体、賦形剤、希釈剤、結合剤、滑沢剤、コーティング剤、崩壊剤又は崩壊補助剤、安定化剤、保存剤、防腐剤、増量剤、分散剤、湿潤化剤、緩衝剤、溶解剤又は溶解補助剤、等張化剤、pH調整剤、噴射剤、着色剤、甘味剤、矯味剤、香料等を適宜添加し、公知の種々の方法にて経口又は非経口的に全身又は局所投与することができる各種製剤形態に調製すればよい。 When the ectodermal cell differentiation inducing agent of the present invention is provided as a pharmaceutical product, a black tea extract is pharmaceutically acceptable and appropriately selected according to the dosage form. Agents, binders, lubricants, coating agents, disintegrants or disintegration aids, stabilizers, preservatives, preservatives, extenders, dispersants, wetting agents, buffers, solubilizers or solubilizers, etc. Various preparations to which a tonicity agent, pH adjusting agent, propellant, coloring agent, sweetening agent, corrigent, fragrance, etc. are appropriately added and can be systemically or locally administered by various known methods orally or parenterally. What is necessary is just to prepare in a form.
経口投与用製剤には、例えば、デンプン、ブドウ糖、ショ糖、果糖、乳糖、ソルビトール、マンニトール、結晶セルロース、炭酸マグネシウム、酸化マグネシウム、リン酸カルシウム、又はデキストリン等の賦形剤;カルボキシメチルセルロース、カルボキシメチルセルロースカルシウム、デンプン、又はヒドロキシプロピルセルロース等の崩壊剤又は崩壊補助剤;ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、アラビアゴム、又はゼラチン等の結合剤;ステアリン酸マグネシウム、ステアリン酸カルシウム、又はタルク等の滑沢剤;ヒドロキシプロピルメチルセルロース、白糖、ポリエチレングリコール、又は酸化チタン等のコーティング剤;ワセリン、流動パラフィン、ポリエチレングリコール、ゼラチン、カオリン、グリセリン、精製水、又はハードファット等の基剤などを用いることができるが、これらに限定はされない。 Preparations for oral administration include, for example, excipients such as starch, glucose, sucrose, fructose, lactose, sorbitol, mannitol, crystalline cellulose, magnesium carbonate, magnesium oxide, calcium phosphate, or dextrin; carboxymethyl cellulose, carboxymethyl cellulose calcium, Disintegrants or disintegration aids such as starch or hydroxypropylcellulose; binders such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gum arabic, or gelatin; lubricants such as magnesium stearate, calcium stearate, or talc Coating agent such as hydroxypropylmethylcellulose, sucrose, polyethylene glycol, or titanium oxide; petrolatum, liquid paraffin, polyethylene Call, gelatin, kaolin, glycerin, purified water, or the like can be used base hard fat, but are not limited to.
非経口投与用製剤には、蒸留水、生理食塩水、エタノール、グリセリン、プロピレングリコール、マクロゴール、ミョウバン水、植物油等の溶剤;ブドウ糖、塩化ナトリウム、D−マンニトール等の等張化剤;無機酸、有機酸、無機塩基又は有機塩基等のpH調整剤などを用いることができるが、これらに限定はされない。 For preparations for parenteral administration, solvents such as distilled water, physiological saline, ethanol, glycerin, propylene glycol, macrogol, alum water, vegetable oil; isotonic agents such as glucose, sodium chloride, D-mannitol; inorganic acids , PH adjusters such as organic acids, inorganic bases or organic bases can be used, but are not limited thereto.
本発明の医薬品の形態としては、特に制限されるものではないが、例えば錠剤、糖衣錠剤、カプセル剤、トローチ剤、顆粒剤、散剤、液剤、丸剤、乳剤、シロップ剤、懸濁剤、エリキシル剤などの経口剤、点眼剤、注射剤(例えば、皮下注射剤、静脈内注射剤、筋肉内注射剤、腹腔内注射剤)、点滴剤、座剤、軟膏剤、ローション剤、噴霧剤、経皮吸収剤、経粘膜吸収剤、貼付剤などの非経口剤などが挙げられる。また、使用する際に再溶解させる乾燥生成物にしてもよい。なお、本発明の医薬品には、動物に用いる薬剤、即ち獣医薬も包含されるものとする。 The form of the pharmaceutical product of the present invention is not particularly limited. For example, tablets, sugar-coated tablets, capsules, troches, granules, powders, liquids, pills, emulsions, syrups, suspensions, elixirs Oral preparations such as eye drops, eye drops, injections (eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), drops, suppositories, ointments, lotions, sprays, transdermal Examples include skin absorption agents, transmucosal absorption agents, and parenteral preparations such as patches. Moreover, you may make it the dry product re-dissolved when using. The pharmaceutical of the present invention includes drugs used for animals, that is, veterinary medicine.
上記製剤中の黒茶抽出物の含有量は特に限定されないが、製剤全重量に対して、黒茶抽出物固形分換算で、0.001〜30重量%の範囲が好ましく、0.01〜10重量%がより好ましい。 The content of the black tea extract in the preparation is not particularly limited, but is preferably in the range of 0.001 to 30% by weight, more preferably 0.01 to 10% by weight in terms of solid content of the black tea extract with respect to the total weight of the preparation. preferable.
0.001重量%以下では効果が低く、また30重量%を超えても効果に大きな増強はみられにくい。又、製剤化における有効成分の添加法については、予め加えておいても、製造途中で添加してもよく、作業性を考えて適宜選択すればよい。 Below 0.001% by weight, the effect is low, and even if it exceeds 30% by weight, the effect is hardly increased. In addition, the method for adding the active ingredient in the formulation may be added in advance or during the production, and may be appropriately selected in consideration of workability.
上記形態の中でも点眼剤の形態とすることが好ましい。黒茶抽出物の含有量は適応疾患等に応じて適宜変更することができるが、点眼剤全体に対して通常0.00001〜5w/v%、好ましくは0.0001〜1w/v%である。点眼剤には、通常点眼剤に配合されうる各種の添加剤を適宜配合することができる。添加剤としては、例えば、緩衝剤(ホウ酸塩緩衝剤、クエン酸塩緩衝剤、酒石酸塩緩衝剤等)、等張化剤(ブドウ糖、マンニトール、ソルビトール等の糖類、グリセリン,ポリエチレングリコール,プロピレングリコール等の多価アルコール類、塩化ナトリウム等の塩類等)、保存剤(塩化ベンザルコニウム、グルコン酸クロルヘキシジン、パラオキシ安息香酸メチル等)、増粘剤(ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、メチルセルロース、カルボキシメチルセルロース等)、安定化剤、抗酸化剤、pH調整剤、キレート剤等が挙げられる。 Among the above forms, the form of eye drops is preferable. The content of the black tea extract can be appropriately changed according to the indication disease and the like, but is usually 0.00001 to 5 w / v%, preferably 0.0001 to 1 w / v% with respect to the whole eye drop. In the eye drops, various additives that can be usually blended in eye drops can be appropriately blended. Examples of additives include buffers (borate buffer, citrate buffer, tartrate buffer, etc.), isotonic agents (sugars such as glucose, mannitol, sorbitol, glycerin, polyethylene glycol, propylene glycol) Polyhydric alcohols such as sodium chloride, salts such as sodium chloride), preservatives (benzalkonium chloride, chlorhexidine gluconate, methyl paraoxybenzoate, etc.), thickeners (hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, etc.) ), Stabilizers, antioxidants, pH adjusters, chelating agents and the like.
また、点眼剤は、公知の水溶液剤の製法に従い調製できる。例えば、医薬上許容される溶媒(例:滅菌精製水、滅菌緩衝液等の水性溶媒)に、上記の各種添加剤を添加した後、黒茶抽出物を溶解して均質な水溶液剤とする。点眼剤の調製は、無菌操作法により行うか、あるいは適当な段階で滅菌処理を施すことにより行われる。 The eye drops can be prepared according to a known aqueous solution preparation method. For example, after adding the above various additives to a pharmaceutically acceptable solvent (eg, aqueous solvent such as sterilized purified water and sterilized buffer), the black tea extract is dissolved to obtain a homogeneous aqueous solution. The eye drops are prepared by aseptic operation or by sterilization at an appropriate stage.
本発明の外胚葉系細胞分化誘導剤は、有効成分である黒茶抽出物が幹細胞から外胚葉系細胞への分化を促進する作用を有するので、眼疾患または神経疾患を改善及び予防するための医薬として有効である。 The ectodermal cell differentiation inducing agent of the present invention has an action of promoting the differentiation from stem cells to ectodermal cells because the black tea extract as an active ingredient has an action to improve and prevent eye diseases or neurological diseases. It is effective as a medicine.
眼疾患としては、水晶体、角膜、網膜、視神経の変性や損傷による疾患であれば特に限定はされないが、例えば、網膜疾患(網膜剥離、網脈絡膜炎、網膜動脈閉塞症、網膜静脈閉塞症、糖尿病性網膜症、高血圧網膜症、加齢黄斑変性症、網膜色素変性症、中心性漿液性網脈絡膜症等)、視神経疾患(緑内障、乳頭浮腫、視神経炎、視神経萎縮等)、角膜疾患(細菌性角膜潰瘍、角膜真菌症、角膜ヘルペス等)、白内障(老人性、糖尿病性、併発性、外傷性の白内障等)などが挙げられる。 The eye disease is not particularly limited as long as it is a disease caused by degeneration or damage of the lens, cornea, retina, and optic nerve. For example, retinal disease (retinal detachment, retina choroiditis, retinal artery occlusion, retinal vein occlusion, diabetes Retinopathy, hypertensive retinopathy, age-related macular degeneration, retinitis pigmentosa, central serous chorioretinopathy, etc.), optic nerve diseases (glaucoma, papilledema, optic neuritis, optic atrophy, etc.), corneal diseases (bacterial) Corneal ulcer, corneal mycosis, corneal herpes, etc.), cataract (senile, diabetic, concomitant, traumatic cataract, etc.).
神経疾患としては、神経系細胞の障害による疾患であれば特に限定はされないが、例えば、脊髄損傷、アルツハイマー病、脊髄小脳変性症、ハンチントン舞踏病、筋萎縮性側索硬化症、脊髄性筋萎縮症、パーキンソン病、多発性硬化症、脳血管障害(脳梗塞、脳卒中、脳動脈瘤)、脳血管障害による痴呆症や運動障害、てんかん、脳外傷などが挙げられる。 The neurological disease is not particularly limited as long as it is a disease caused by a nervous system cell, for example, spinal cord injury, Alzheimer's disease, spinocerebellar degeneration, Huntington's chorea, amyotrophic lateral sclerosis, spinal muscular atrophy. Disease, Parkinson's disease, multiple sclerosis, cerebrovascular disorder (cerebral infarction, stroke, cerebral aneurysm), dementia and movement disorder due to cerebrovascular disorder, epilepsy, cerebral trauma and the like.
本発明の医薬品は上記疾患の発症を抑制する予防薬として、及び/又は、正常な状態に改善する治療薬として機能する。 The pharmaceutical agent of the present invention functions as a prophylactic agent that suppresses the onset of the above diseases and / or a therapeutic agent that improves the normal state.
本発明の医薬品を前述の疾患の予防及び/又は治療用医薬として用いる場合、ヒト、マウス、ラット、ウサギ、イヌ、ネコ等の哺乳動物に対して広い範囲の投与量で経口的にまたは非経口的に投与することができる。 When the pharmaceutical agent of the present invention is used as a pharmaceutical agent for the prevention and / or treatment of the aforementioned diseases, it is orally or parenterally administered over a wide range of doses to mammals such as humans, mice, rats, rabbits, dogs and cats. Can be administered.
本発明の医薬品の投与量は、疾患の種類、投与対象の年齢、性別、体重、症状の程度などに応じて適宜決定することができる。例えば、成人に経口投与する場合には、一日の投与量は、黒茶抽出物として1〜1000mg、好ましくは5〜200mgである。 The dosage of the pharmaceutical agent of the present invention can be appropriately determined according to the type of disease, the age, sex, body weight, symptom level, etc. of the administration subject. For example, when orally administered to an adult, the daily dose is 1 to 1000 mg, preferably 5 to 200 mg, as a black tea extract.
また、本発明の外胚葉系細胞分化誘導剤は、飲食品にも配合できる。本発明において、飲食品とは、健康食品、機能性食品、栄養補助食品、または特定保健用食品を含む意味で用いられる。さらに、本発明の飲食品をヒト以外の哺乳動物を対象として使用される場合には、ペットフード、飼料を含む意味で用いることができる。特に、アルツハイマー病などの予防や神経損傷の治療など長期にわたって服用が必要となる場合に、日常的に摂取できる上で有利である。 Moreover, the ectodermal cell differentiation-inducing agent of the present invention can also be added to food and drink. In the present invention, the food / beverage product is used to mean including a health food, a functional food, a dietary supplement, or a food for specified health use. Furthermore, when using the food-drinks of this invention for mammals other than a human, it can be used by the meaning containing pet food and feed. In particular, it is advantageous in that it can be taken on a daily basis when it is necessary for long-term use such as prevention of Alzheimer's disease or treatment of nerve damage.
飲食品の形態は、食用に適した形態、例えば、固形状、液状、顆粒状、粒状、粉末状、カプセル状、クリーム状、ペースト状のいずれであってもよい。 The form of the food or drink may be any form suitable for edible use, for example, solid, liquid, granular, granular, powder, capsule, cream, or paste.
飲食品の種類としては、具体的には、食パン、菓子パン等のパン類;そば、うどん、パスタ、中華麺、即席麺等の麺類;キャンディー、チューインガム、チョコレート、ビスケット・クッキー等の焼き菓子、ゼリー等の菓子類;アイスクリーム、アイスシャーベット、かき氷等の冷菓;加工乳、発酵乳、ヨーグルト、バター、チーズ等の乳製品;かまぼこ、ちくわ、ハム、ソーセージ等の水産・畜産加工食品;マーガリン、マヨネーズ、ショートニング、ホイップクリーム、ドレッシング等の油脂及び油脂加工食品;しょうゆ、ソース、酢、みりん等の調味料;清涼飲料、炭酸飲料、美容ドリンク、栄養飲料、果実飲料、乳飲料などの飲料(これらの飲料の濃縮原液及び調製用粉末を含む)等が挙げられるが、これらに限定はされない。 Specific types of food and drink include breads such as bread and confectionery bread; noodles such as buckwheat, udon, pasta, Chinese noodles and instant noodles; baked confectionery such as candy, chewing gum, chocolate, biscuits and cookies, jelly Confectionery such as ice cream, ice sherbet, shaved ice; dairy products such as processed milk, fermented milk, yogurt, butter, cheese; fishery and livestock processed foods such as kamaboko, chikuwa, ham, sausage; margarine, mayonnaise , Shortening, whipped cream, dressing and other fats and oils processed foods; seasonings such as soy sauce, sauce, vinegar, mirin; soft drinks, carbonated drinks, beauty drinks, nutrition drinks, fruit drinks, milk drinks, etc. (these Including, but not limited to, beverage concentrate concentrates and powders for preparation).
本発明の飲食品は、その種類に応じて通常使用される添加物を適宜配合してもよい。添加物としては、食品衛生上許容されうる添加物であればいずれも使用できるが、例えば、ブドウ糖、ショ糖、果糖、異性化液糖、アスパルテーム、ステビア等の甘味料;クエン酸、リンゴ酸、酒石酸等の酸味料;デキストリン、澱粉等の賦形剤;結合剤、希釈剤、香料、着色料、緩衝剤、増粘剤、ゲル化剤、安定剤、保存剤、乳化剤、分散剤、懸濁化剤、防腐剤などが挙げられる。 The food / beverage products of the present invention may be appropriately blended with additives usually used depending on the type. As the additive, any food hygiene-acceptable additive can be used. For example, sweeteners such as glucose, sucrose, fructose, isomerized liquid sugar, aspartame, stevia; citric acid, malic acid, Acidic agents such as tartaric acid; excipients such as dextrin and starch; binders, diluents, fragrances, colorants, buffers, thickeners, gelling agents, stabilizers, preservatives, emulsifiers, dispersants, suspensions Agents, preservatives and the like.
本発明の飲食品における黒茶抽出物の配合量は、幹細胞から外胚葉系細胞への分化促進作用が発揮できる量であればよいが、対象飲食品の一般的な摂取量、飲食品の形態、効能・効果、呈味性、嗜好性及びコストなどを考慮して適宜設定すればよい。 The blending amount of the black tea extract in the food or drink of the present invention may be an amount that can exert the differentiation promoting action from stem cells to ectoderm cells, but the general intake of the target food or drink, the form of the food or drink It may be set as appropriate in consideration of efficacy / effect, taste, palatability and cost.
以下、実施例により本発明をさらに具体的に説明する。但し、本発明はこれらに限定されるものではない。実施例に示す配合量の部とは重量部を、%とは重量%を示す。 Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to these. In the examples, the part of the amount is part by weight, and% is% by weight.
(実施例1)黒茶抽出物の製造
(1) 製造例1:黒茶の熱水抽出物
黒茶(バタバタ茶)20gに精製水400gを加え、95〜100℃で2時間抽出した後、濾過し、そのろ液を濃縮し、凍結乾燥して黒茶の熱水抽出物を2.9g得た。
(Example 1) Production of black tea extract
(1) Production Example 1: Hot water extract of black tea 400 g of purified water was added to 20 g of black tea (butterfly tea), extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated and frozen. It dried and obtained 2.9g of hot water extracts of black tea.
(2) 製造例2:黒茶の50%エタノール抽出物
黒茶(バタバタ茶)20gに50%エタノール200gを加え、常温で3日間抽出した後、濾過し、そのろ液を濃縮乾固して、黒茶のエタノール抽出物を2.5g得た。
(2) Production Example 2: 50% ethanol extract of black tea 200g of 50% ethanol was added to 20g of black tea (Batabata tea), extracted for 3 days at room temperature, filtered, and the filtrate was concentrated to dryness. 2.5 g of black tea ethanol extract was obtained.
(3) 製造例3:黒茶の50%1,3−ブチレングリコール抽出物
黒茶(バタバタ茶)20gに精製水200g及び1,3−ブチレングリコール200gを加え、常温で7日間抽出した後、濾過し、黒茶の50%1,3−ブチレングリコール抽出物を360g得た。
(3) Production Example 3: 50% 1,3-butylene glycol extract of black tea After adding 200 g of purified water and 200 g of 1,3-butylene glycol to 20 g of black tea (Batabata tea), the mixture was extracted at room temperature for 7 days. Filtration yielded 360 g of 50% 1,3-butylene glycol extract of black tea.
(実施例2)黒茶抽出物による幹細胞(マウスES細胞)の外胚葉系細胞への分化誘導
(1) ES細胞の調製
ゼラチンコート処理した35mmシャーレにMMC処理済みのMEFをコンフルエントの状態で培養し、その上にマウスES細胞を10〜20×104個播種し、37℃、5%CO2インキュベーターで前培養した。培地はDMEMにchemicon社製のES細胞用添加因子(L-グルタミン液、2メルカプトエタノール液、ヌクレオシド液、非必須アミノ酸液)を推奨濃度で添加した後、LIFを1000units/mL、Fetal Bovine Serum(FBS)を15%添加したES細胞未分化維持用培地(以下、「ES細胞用培地」という)を用いた。
(Example 2) Differentiation induction of stem cells (mouse ES cells) into ectoderm cells by black tea extract
(1) Preparation of ES cells Cultivate MMC-treated MEF in a gelatin-coated 35 mm petri dish in a confluent state, and inoculate 10-20 × 10 4 mouse ES cells on it, at 37 ° C., 5% CO Pre-cultured in 2 incubators. The medium was added to DMEM with chemicon's additional factor for ES cells (L-glutamine solution, 2 mercaptoethanol solution, nucleoside solution, non-essential amino acid solution) at the recommended concentration, then LIF 1000 units / mL, Fetal Bovine Serum ( An ES cell undifferentiated maintenance medium (hereinafter referred to as “ES cell medium”) supplemented with 15% FBS) was used.
上記の方法で培養したES細胞及びMEFをトリプシン処理によりシャーレから剥がし、それらを再びゼラチンコート処理した35mmシャーレに播種した。播種後30分間静置し、その後培地を別のチューブに回収した。このとき接着性の強いMEFはシャーレに残り、ES細胞のみが回収される。このようにして回収した未分化なES細胞を用いて以下の実験を行った。 The ES cells and MEF cultured by the above method were detached from the petri dish by trypsin treatment and seeded again in a 35 mm petri dish treated with gelatin. After seeding, the mixture was allowed to stand for 30 minutes, and then the medium was collected in another tube. At this time, MEF having strong adhesiveness remains in the petri dish, and only ES cells are collected. The following experiment was performed using the undifferentiated ES cells collected in this manner.
(2) フィーダー細胞を用いた培養系における黒茶抽出物による幹細胞の外胚葉系細胞への分化誘導
MEFから分離したES細胞を、24wellプレートで培養したMMC処理済のMEF上に再び播種し(5×104 cells/well)、ES細胞用培地からLIFを除いた培地を用いて培養した。その際、前記製造例1で調製した黒茶抽出物を25.0、50.0、100.0μg/mLの濃度で添加した。
(2) Induction of differentiation of stem cells into ectoderm cells by black tea extract in a culture system using feeder cells
ES cells separated from MEFs were seeded again on MMC-treated MEFs cultured in 24 well plates (5 × 10 4 cells / well), and cultured using a medium obtained by removing LIF from the ES cell medium. At that time, the black tea extract prepared in Production Example 1 was added at concentrations of 25.0, 50.0, and 100.0 μg / mL.
培養4日後にES細胞のみを回収し、細胞をPBS(-)にて2回洗浄し、Trizol Reagent(Invitrogen)によって細胞からRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems)を用いて、RNAをcDNAに逆転写後、ABI7300(Applied Biosystems)により、下記の各プライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、Nanog(未分化マーカー: Cell Res. 2007 Jan; 17(1):42-9. Review. Nanog and transcriptional networks in embryonic stem cell pluripotency. Pan G, Thomson JA.)、Otx2(外胚葉・神経細胞マーカー)、Sox1(神経細胞マーカー)、Six3(前脳領域、眼の分化マーカー)の各マーカー遺伝子の発現を確認した。その他の操作は定められた方法に従って実施した。 After 4 days of culture, only ES cells were collected, the cells were washed twice with PBS (−), and RNA was extracted from the cells with Trizol Reagent (Invitrogen). After reverse transcription of RNA to cDNA using 2-STEP real-time PCR kit (Applied Biosystems), real-time PCR (95 ° C: 15 seconds, 60 ° C: 30 ° C) using the following primer sets using ABI7300 (Applied Biosystems) Nanocycle (Undifferentiated marker: Cell Res. 2007 Jan; 17 (1): 42-9. Review. Nanog and transcriptional networks in embryonic stem cell pluripotency. Pan G, Thomson JA.), Otx2 (Expression of ectoderm / nerve cell marker), Sox1 (nerve cell marker), Six3 (forebrain region, eye differentiation marker) expression of each marker gene was confirmed. Other operations were carried out in accordance with established methods.
Nanog (未分化マーカー)用プライマーセット:
ATGCCTGCAGTTTTTCATCC(配列番号1)
GAGGCAGGTCTTCAGAGGAA(配列番号2)
Otx2(外胚葉、神経細胞マーカー)用プライマーセット:
GAAAATCAACTTGCCAGAATCCA(配列番号3)
GCGGCACTTAGCTCTTCGAT(配列番号4)
Sox1(神経細胞マーカー)用プライマーセット:
GCCGAGTGGAAGGTCATGT(配列番号5)
TGTAATCCGGGTGTTCCTTCAT(配列番号6)
Six3(前脳領域)用プライマーセット:
CCCTAGATCTCTATTCCTCCCACTTC(配列番号7)
GAAGTAGGGAGCAGTGGTGAGAA(配列番号8)
Gapdh(内部標準)用プライマーセット:
CCGTGTTCCTACCCCCAAT(配列番号9)
TGCCTGCTTCACCACCTTCT(配列番号10)
Primer set for Nanog (undifferentiated marker):
ATGCCTGCAGTTTTTCATCC (SEQ ID NO: 1)
GAGGCAGGTCTTCAGAGGAA (SEQ ID NO: 2)
Primer set for Otx2 (ectoderm, nerve cell marker):
GAAAATCAACTTGCCAGAATCCA (SEQ ID NO: 3)
GCGGCACTTAGCTCTTCGAT (SEQ ID NO: 4)
Sox1 (nerve cell marker) primer set:
GCCGAGTGGAAGGTCATGT (SEQ ID NO: 5)
TGTAATCCGGGTGTTCCTTCAT (SEQ ID NO: 6)
Six3 (forebrain region) primer set:
CCCTAGATCTCTATTCCTCCCACTTC (SEQ ID NO: 7)
GAAGTAGGGAGCAGTGGTGAGAA (SEQ ID NO: 8)
Primer set for Gapdh (internal standard):
CCGTGTTCCTACCCCCAAT (SEQ ID NO: 9)
TGCCTGCTTCACCACCTTCT (SEQ ID NO: 10)
各細胞のマーカー遺伝子の発現については、黒茶抽出物を添加せずに培養した細胞における各遺伝子mRNAの発現量を内部標準であるGapdh mRNAの発現量に対する割合として算出した相対発現量(各遺伝子の発現量/Gapdh発現量)の値を1.0とし、これに対し、黒茶抽出物を添加して分化誘導した各細胞における各遺伝子相対発現量の値を算出し、評価した。その結果を表1に示す。 Regarding the expression of the marker gene in each cell, the relative expression level (each gene was calculated as the ratio of the expression level of each gene mRNA in the cells cultured without adding black tea extract to the expression level of Gapdh mRNA as an internal standard. The value of the relative expression level of each gene in each cell induced to differentiate by adding black tea extract was calculated and evaluated. The results are shown in Table 1.
表1に示されるように、未分化マーカーであるNanogは黒茶抽出物の濃度依存的に発現が抑制された。一方で、外胚葉や神経細胞マーカーであるOtx2やSox1に関してはその発現が促進されることが明らかとなった。また、外胚葉の中でも初期胚の発生過程で、前脳領域で発現が促進される遺伝子であるSix3の発現も促進された。 As shown in Table 1, expression of Nanog, an undifferentiated marker, was suppressed depending on the concentration of the black tea extract. On the other hand, the expression of ectodermal and neuronal markers Otx2 and Sox1 was clarified. Moreover, the expression of Six3, a gene whose expression is promoted in the forebrain region, was also promoted during the development of the early embryo among the ectoderm.
(3) フィーダー細胞を用いない培養系における黒茶抽出物による幹細胞の外胚葉系細胞への分化誘導
MEFから分離した未分化なES細胞をゼラチンコート処理した24wellプレートに直接(MEFなしの状態で)播種し(5×104 cells/well)、上記方法と同様にES細胞用培地からLIFを除いた培地を用いて培養し、各濃度の黒茶抽出物を添加した。培養4日後にRNAを回収し、各マーカー遺伝子の発現をリアルタイムPCRにより解析した。その結果を表2に示す。
(3) Induction of differentiation of stem cells into ectoderm cells by black tea extract in a culture system without feeder cells
Undifferentiated ES cells separated from MEF were seeded directly in gelatin-coated 24-well plates (without MEF) (5 × 10 4 cells / well), and LIF was removed from the ES cell medium in the same manner as above. The black tea extract of each concentration was added. After 4 days of culture, RNA was collected and the expression of each marker gene was analyzed by real-time PCR. The results are shown in Table 2.
表2に示されるように、(2)の場合と同様、Nanogの発現抑制、Otx2、Sox1、Six3の発現促進が確認された。 As shown in Table 2, as in the case of (2), Nanog expression suppression and Otx2, Sox1, and Six3 expression promotion were confirmed.
(4) EBを形成する培養系における黒茶抽出物による幹細胞の外胚葉系細胞への分化誘導
MEFから分離した未分化なマウスES細胞を、LIFを除いたES細胞用培地に懸濁し、2000cells/20μLの細胞濃度でhanging dropを形成し、EB(embryoid body)を作製した。その際、各濃度の黒茶抽出物を添加し、培養4日後にRNAを回収し、Nanog(未分化マーカー)、Otx2(外胚葉・神経細胞マーカー)、Sox1(神経細胞マーカー)、Six3(前脳領域マーカー)の各マーカー遺伝子の発現をリアルタイムPCRにより解析した。その結果を表3に示す。
(4) Stem cell differentiation into ectodermal cells induced by black tea extract in a culture system that forms EB
Undifferentiated mouse ES cells separated from MEF were suspended in a medium for ES cells excluding LIF, and hanging drops were formed at a cell concentration of 2000 cells / 20 μL to prepare EB (embryoid body). At that time, black tea extract of each concentration was added, and RNA was collected after 4 days of culture. Nanog (undifferentiation marker), Otx2 (ectodermal / neural cell marker), Sox1 (neural cell marker), Six3 (previous) The expression of each marker gene (brain area marker) was analyzed by real-time PCR. The results are shown in Table 3.
表3に示されるように、(2)の場合と同様、Nanogの発現抑制、Otx2、Sox1、Six3の発現促進が確認された。 As shown in Table 3, as in the case of (2), Nanog expression suppression and Otx2, Sox1 and Six3 expression promotion were confirmed.
上記表1〜3の結果から、いずれの培養系(フィーダー細胞を用いた培養系、フィーダー細胞を用いない培養系、EBを形成する培養系)においても黒茶抽出物はマウスES細胞の未分化維持を抑制し、一方で外胚葉系細胞への分化を促進することが明らかとなった。 From the results shown in Tables 1 to 3 above, black tea extract is an undifferentiated mouse ES cell in any culture system (culture system using feeder cells, culture system not using feeder cells, culture system forming EB). It was found to suppress maintenance while promoting differentiation to ectoderm cells.
(実施例3)黒茶抽出物による幹細胞(マウスES細胞)の神経細胞への分化誘導
無血清培養下、ES細胞を各種のストローマ細胞と共培養することにより、成熟した神経系細胞を分化誘導する技術が確立されている(特許4294482号; Kawasaki H, Mizuseki K, Nishikawa S, Kaneko S, Kuwana Y, Nakanishi S, Nishikawa SI, Sasai Y., Neuron. 2000 Oct;28(1):31-40. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity)。そこで、本神経分化誘導系に黒茶抽出物を添加し、成熟した神経細胞への誘導が促進されるか検討した。
(Example 3) Differentiation induction of stem cells (mouse ES cells) into neurons by black tea extract Induction of differentiation of mature nervous system cells by co-culturing ES cells with various stromal cells in serum-free culture Technology has been established (Patent No. 4294482; Kawasaki H, Mizuseki K, Nishikawa S, Kaneko S, Kuwana Y, Nakanishi S, Nishikawa SI, Sasai Y., Neuron. 2000 Oct; 28 (1): 31-40 Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity). Therefore, it was investigated whether black tea extract was added to this neural differentiation induction system to promote induction into mature neurons.
MEFから分離したマウス未分化ES細胞を、24wellプレートでコンフルエントまで培養したST2細胞(マウス骨髄由来ストローマ細胞)上に500cells/wellの濃度で播種し、G-MEMに10% KnockOut. Serum Replacement(KSR)、2mM L-グルタミン、1mM pyruvate、0.1mM 2メルカプトエタノール液、0.1mM 非必須アミノ酸液を添加した神経細胞分化誘導培地で培養した。その際、黒茶抽出物を100μg/mLの濃度で添加した。 Mouse undifferentiated ES cells isolated from MEF were seeded at a concentration of 500 cells / well on ST2 cells (mouse bone marrow-derived stromal cells) cultured to confluence in 24-well plates, and 10% KnockOut. Serum Replacement (KSR) was added to G-MEM. ), 2 mM L-glutamine, 1 mM pyruvate, 0.1 mM 2 mercaptoethanol solution, 0.1 mM non-essential amino acid solution, and cultured in a neuronal differentiation induction medium. At that time, black tea extract was added at a concentration of 100 μg / mL.
分化誘導12日後にST2細胞及びES細胞を回収し、神経細胞分化マーカー遺伝子であるPax6(神経前駆細胞マーカー)、Tuj-1(神経細胞マーカー)、Map2(成熟神経細胞マーカー)の発現を下記の各プライマーセットを用いてリアルタイムPCRにより解析した。 ST2 cells and ES cells were collected 12 days after differentiation induction, and expression of Pax6 (neural progenitor cell marker), Tuj-1 (neural cell marker), and Map2 (mature neuronal cell marker), which are neuronal cell differentiation marker genes, were as follows: Each primer set was analyzed by real-time PCR.
Pax6(神経前駆細胞マーカー):
GCACCAAAGGGTCATCGC(配列番号11)
TGGGGGGTGGATGGAAG(配列番号12)
Tuj-1(神経細胞マーカー):
CTCAAAATGTCATCCACCTT(配列番号13)
GTGAACTCCATCTCATCCAT(配列番号14)
Map2(成熟神経細胞マーカー):
ACTCAGCAACGTCTCATCTT(配列番号15)
GTATTCACAAGCCCTGCTTA(配列番号16)
Pax6 (neural progenitor cell marker):
GCACCAAAGGGTCATCGC (SEQ ID NO: 11)
TGGGGGGTGGATGGAAG (SEQ ID NO: 12)
Tuj-1 (nerve cell marker):
CTCAAAATGTCATCCACCTT (SEQ ID NO: 13)
GTGAACTCCATCTCATCCAT (SEQ ID NO: 14)
Map2 (mature neural cell marker):
ACTCAGCAACGTCTCATCTT (SEQ ID NO: 15)
GTATTCACAAGCCCTGCTTA (SEQ ID NO: 16)
リアルタイムPCRによる各マーカー遺伝子の発現の解析結果を表4に示す。
表4に示されるように、黒茶抽出物により、各神経細胞分化マーカーの発現が顕著に促進されることが確認された。以上の結果から黒茶抽出物はES細胞から神経細胞への分化を顕著に促進することが明らかとなった。 As shown in Table 4, it was confirmed that the expression of each neuronal differentiation marker was significantly promoted by the black tea extract. From the above results, it was clarified that the black tea extract significantly promotes differentiation from ES cells to neurons.
(実施例4)黒茶抽出物による幹細胞(マウスES細胞)の眼様構造体への分化誘導
ES細胞をストローマ細胞であるST2細胞と共培養することにより、メラノサイトを分化誘導する系が確立されている(Yamane T, Hayashi S, Mizoguchi M, Yamazaki H, Kunisada T., Dev Dyn. 1999 Dec;216 (4-5):450-8. Derivation of melanocytes from embryonic stem cells in culture.)。本分化誘導系では、メラノサイト以外にも、心筋細胞、血球系細胞等様々な細胞が分化してくることが知られている。このような様々な細胞が分化してくる系に、黒茶抽出物を添加することにより、いずれの細胞への誘導が促進されるか検討した。
(Example 4) Differentiation induction of stem cells (mouse ES cells) into eye-like structures by black tea extract
A system for inducing differentiation of melanocytes has been established by co-culturing ES cells with ST2 cells, which are stromal cells (Yamane T, Hayashi S, Mizoguchi M, Yamazaki H, Kunisada T., Dev Dyn. 1999 Dec; 216 (4-5): 450-8. Derivation of melanocytes from embryonic stem cells in culture.). In this differentiation induction system, it is known that various cells such as cardiomyocytes and blood cells are differentiated in addition to melanocytes. We examined which cell induction was promoted by adding black tea extract to such a system in which various cells differentiate.
MEFから分離したマウス未分化ES細胞を、24wellプレートでコンフルエントまで培養したST2細胞上に500cells/wellの濃度で播種し、α-MEMに10% FBS、100nM DEX、20pM bFGF、10pM CT、100ng/mL EDN3を含む分化誘導培地で分化を促した。その際、黒茶抽出物を100μg/mLの濃度で添加した。 Mouse undifferentiated ES cells isolated from MEF were seeded at a concentration of 500 cells / well on ST2 cells cultured to confluence in a 24-well plate, and α-MEM was 10% FBS, 100 nM DEX, 20 pM bFGF, 10 pM CT, 100 ng / Differentiation was promoted with a differentiation induction medium containing mL EDN3. At that time, black tea extract was added at a concentration of 100 μg / mL.
図1に上記分化誘導試験結果を示す。黒茶抽出物未添加群では、誘導後数日でES細胞のコロニーができ、誘導12日目には様々な形態をした細胞が現れ始めた。一方、黒茶抽出物添加群では、誘導後数日でコロニーができたがその形態は未添加群とは顕著に異なっており、誘導12日目の時点でコロニーの周りに色素を有した構造体が多数出現し始めた。 FIG. 1 shows the results of the differentiation induction test. In the black tea extract non-added group, colonies of ES cells were formed within a few days after induction, and cells having various morphologies began to appear on the 12th day of induction. On the other hand, in the black tea extract added group, colonies were formed within a few days after induction, but the form was significantly different from the non-added group, and the structure had pigment around the colony at the 12th day of induction. Many bodies began to appear.
ES細胞から網膜色素上皮細胞や水晶体(レンズ)を含む眼様構造体を誘導する系が確立されている(Hirano M, Yamamoto A, Yoshimura N, Tokunaga T, Motohashi T, Ishizaki K, Yoshida H, Okazaki K, Yamazaki H, Hayashi S, Kunisada T., Dev Dyn. 2003 Dec;228(4):664-71. Generation of structures formed by lens and retinal cells differentiating from embryonic stem cells.)。上記コロニーの形態を顕微鏡観察すると、黒茶抽出物添加により形成された構造体は、上記文献で報告される眼様構造体に酷似していた(図1)。 A system has been established to induce eye-like structures including retinal pigment epithelial cells and lenses (lenses) from ES cells (Hirano M, Yamamoto A, Yoshimura N, Tokunaga T, Motohashi T, Ishizaki K, Yoshida H, Okazaki K, Yamazaki H, Hayashi S, Kunisada T., Dev Dyn. 2003 Dec; 228 (4): 664-71. Generation of structures formed by lens and retinal cells differentiating from embryonic stem cells.). When the morphology of the colony was observed with a microscope, the structure formed by adding the black tea extract was very similar to the eye-like structure reported in the above literature (FIG. 1).
また、分化誘導12日目において、細胞を回収し、眼の分化マーカー遺伝子であるOtx2(前脳領域、眼の分化マーカー)、Six3(前脳領域、眼の分化マーカー)、Pax6(眼の分化マーカー)、Crystalin(水晶体マーカー)の発現を下記の各プライマーセットを用いてリアルタイムPCRにより解析した。 On the 12th day of differentiation induction, cells were collected, and Otx2 (forebrain region, eye differentiation marker), Six3 (forebrain region, eye differentiation marker), Pax6 (eye differentiation marker) The expression of the marker) and Crystalin (lens marker) were analyzed by real-time PCR using the following primer sets.
Otx2(前脳領域、眼の分化マーカー):
GAAAATCAACTTGCCAGAATCCA(配列番号3)
GCGGCACTTAGCTCTTCGAT(配列番号4)
Six3(前脳領域、眼の分化マーカー):
CCCTAGATCTCTATTCCTCCCACTTC(配列番号7)
GAAGTAGGGAGCAGTGGTGAGAA(配列番号8)
Pax6 (眼の分化マーカー):
GCACCAAAGGGTCATCGC(配列番号11)
TGGGGGGTGGATGGAAG(配列番号12)
Crystalin(水晶体マーカー):
TGGCTGCTGGATGCTCTATG(配列番号17)
CCGCGACGCAGGAAGTA(配列番号18)
Otx2 (forebrain region, eye differentiation marker):
GAAAATCAACTTGCCAGAATCCA (SEQ ID NO: 3)
GCGGCACTTAGCTCTTCGAT (SEQ ID NO: 4)
Six3 (forebrain region, eye differentiation marker):
CCCTAGATCTCTATTCCTCCCACTTC (SEQ ID NO: 7)
GAAGTAGGGAGCAGTGGTGAGAA (SEQ ID NO: 8)
Pax6 (eye differentiation marker):
GCACCAAAGGGTCATCGC (SEQ ID NO: 11)
TGGGGGGTGGATGGAAG (SEQ ID NO: 12)
Crystalin:
TGGCTGCTGGATGCTCTATG (SEQ ID NO: 17)
CCGCGACGCAGGAAGTA (SEQ ID NO: 18)
リアルタイムPCRによる各マーカー遺伝子の発現の解析結果を表5に示す。
表5に示すように、黒茶抽出物添加により、眼の発生マーカー(Otx2,Six3,Pax6,Crystalin)の発現が促進されることが確認された。 As shown in Table 5, it was confirmed that the addition of black tea extract promotes the expression of ocular developmental markers (Otx2, Six3, Pax6, Crystalin).
以上の結果から、黒茶抽出物はES細胞から網膜色素上皮や水晶体等を含む眼様構造体への誘導を促進することが明らかとなった。 From the above results, it was clarified that the black tea extract promotes the induction from the ES cells to the eye-like structure including the retinal pigment epithelium and the lens.
(実施例5)黒茶抽出物による幹細胞(ヒトiPS細胞)の外胚葉系細胞への分化誘導
(1) ヒトiPS細胞の調製
ゼラチンコート処理した60mmシャーレにMMC処理済みのMEFをコンフルエントの状態で培養し、その上に解凍したヒトiPS細胞の細胞塊を播種し、37℃、5%CO2インキュベーターで前培養した。培地はカルディオ社製のiPSellonに5ng/mLの濃度でbFGFを添加したiPS細胞未分化維持用培地(以下、「iPS細胞用培地」という)を用いた。
(Example 5) Differentiation induction of stem cells (human iPS cells) into ectoderm cells by black tea extract
(1) Preparation of human iPS cells MFC-treated MEF was cultured in a gelatin-coated 60 mm petri dish in a confluent state, and thawed human iPS cell mass was seeded at 37 ° C, 5% CO 2 Pre-cultured in an incubator. The medium was an iPS cell undifferentiated maintenance medium (hereinafter referred to as “iPS cell culture medium”) in which bFGF was added at a concentration of 5 ng / mL to iPSellon manufactured by Cardio.
上記の方法で培養したiPS細胞をinvitrogen社製のEZPassageを用いてコロニーを切断し、回収した後、24wellプレートで培養したMMC処理済のMEF上に再び播種し、iPS細胞用培地からbFGFを除いた培地を用いて培養した。その際、黒茶抽出物を100μg/mLの濃度で添加した。 The iPS cells cultured by the above method were cut and recovered using EZPassage manufactured by invitrogen, and then seeded again on MMC-treated MEF cultured in a 24-well plate, and bFGF was removed from the iPS cell culture medium. The culture medium was cultured using the same medium. At that time, black tea extract was added at a concentration of 100 μg / mL.
培養4日後にRNAを回収し、Nanog(未分化マーカー)、Otx2(外胚葉・神経細胞マーカー)、Sox1(神経細胞マーカー)の各マーカー遺伝子の発現を下記の各プライマーセットを用いてリアルタイムPCRにより解析した。その結果を表6に示す。 RNA was collected after 4 days of culture, and expression of each marker gene of Nanog (undifferentiation marker), Otx2 (ectodermal / neural cell marker), and Sox1 (neural cell marker) was performed by real-time PCR using the following primer sets: Analyzed. The results are shown in Table 6.
Nanog (未分化マーカー)用プライマーセット:
CCTTCCTCCATGGATCTGCTT(配列番号19)
AAGTGGGTTGTTTGCCTTTGG(配列番号20)
Otx2(外胚葉、神経細胞マーカー)用プライマーセット:
TTCACTCGGGCGCAGCTAG(配列番号21)
CCATACCTGCACCCTCGACTC(配列番号22)
Sox1(神経細胞マーカー)用プライマーセット:
GGTCAAACGGCCCATGAAC(配列番号23)
TGATCTCCGAGTTGTGCATCTT(配列番号24)
Six3(前脳領域)用プライマーセット:
GTATTCCGCTCCCCCCTAGA(配列番号25)
TGGTGAGAATCGGCGAAGTT(配列番号26)
Gapdh(内部標準)用プライマーセット:
TGCACCACCAACTGCTTAGC(配列番号27)
TCTTCTGGGTGGCAGTGATG(配列番号28)
Primer set for Nanog (undifferentiated marker):
CCTTCCTCCATGGATCTGCTT (SEQ ID NO: 19)
AAGTGGGTTGTTTGCCTTTGG (SEQ ID NO: 20)
Primer set for Otx2 (ectoderm, nerve cell marker):
TTCACTCGGGCGCAGCTAG (SEQ ID NO: 21)
CCATACCTGCACCCTCGACTC (SEQ ID NO: 22)
Sox1 (nerve cell marker) primer set:
GGTCAAACGGCCCATGAAC (SEQ ID NO: 23)
TGATCTCCGAGTTGTGCATCTT (SEQ ID NO: 24)
Six3 (forebrain region) primer set:
GTATTCCGCTCCCCCCTAGA (SEQ ID NO: 25)
TGGTGAGAATCGGCGAAGTT (SEQ ID NO: 26)
Primer set for Gapdh (internal standard):
TGCACCACCAACTGCTTAGC (SEQ ID NO: 27)
TCTTCTGGGTGGCAGTGATG (SEQ ID NO: 28)
表6に示されるように、マウスES細胞を用いた場合と同様、Nanogの発現抑制、Otx2、Sox1、Six3の発現促進が確認された。 As shown in Table 6, as in the case of using mouse ES cells, Nanog expression suppression and Otx2, Sox1, and Six3 expression promotion were confirmed.
以上より、黒茶抽出物はヒトiPS細胞に対しても外胚葉分化誘導促進効果を示すことが明らかとなった。 From the above, it was clarified that the black tea extract exhibits an ectodermal differentiation induction promoting effect on human iPS cells.
(実施例6)黒茶抽出物による体性幹細胞の外胚葉系細胞への分化誘導
ヒトやマウスの体性幹細胞から神経細胞を分化誘導する系が確立されている(Stem Cells Dev. 2008 Oct;17(5):909-16.Neuronal differentiation potential of human adipose-derived mesenchymal stem cells. Anghileri E, Marconi S, Pignatelli A, Cifelli P, Galie M, Sbarbati A, Krampera M, Belluzzi O, Bonetti B.SourceDepartment of Neurological Sciences and Vision, University of Verona, Verona, Italy.)。この分化誘導系に黒茶抽出物を添加したところ、実施例3と同様に、神経細胞への分化が有意に促進されることが確認された。よって、黒茶抽出物はES細胞やiPS細胞を用いた場合と同様に、体性幹細胞に対しても外胚葉への分化を顕著に促進することが明らかとなった。
(Example 6) Differentiation induction of somatic stem cells into ectoderm cells by black tea extract A system for inducing differentiation of neurons from human or mouse somatic stem cells has been established (Stem Cells Dev. 2008 Oct; 17 (5): 909-16.Neuronal differentiation potential of human adipose-derived mesenchymal stem cells.Anghileri E, Marconi S, Pignatelli A, Cifelli P, Galie M, Sbarbati A, Krampera M, Belluzzi O, Bonetti B. SourceDepartment of Neurological Sciences and Vision, University of Verona, Verona, Italy.). When black tea extract was added to this differentiation induction system, it was confirmed that differentiation into nerve cells was significantly promoted as in Example 3. Therefore, it was clarified that the black tea extract significantly promotes differentiation into ectoderm for somatic stem cells as in the case of using ES cells and iPS cells.
本発明の外胚葉系細胞分化誘導剤は、幹細胞から眼の構成細胞や神経細胞などの外胚葉系細胞を効率的に分化誘導できる。分化誘導された眼様組織や神経細胞は、損傷部位への移植、人工神経・人工網膜としての利用など、再生医療分野において利用できる。また、白内障、緑内障、網膜剥離などの眼疾患や神経疾患の根本的治療を目的とした医薬品、医薬部外品、機能性食品やサプリメントなどの飲食品の製造分野において利用できる。 The ectodermal cell differentiation-inducing agent of the present invention can efficiently induce differentiation of ectodermal cells such as eye constituent cells and nerve cells from stem cells. Differentiated eye-like tissues and nerve cells can be used in the field of regenerative medicine, such as transplantation to an injured site and use as an artificial nerve / artificial retina. It can also be used in the field of manufacturing foods and drinks such as pharmaceuticals, quasi drugs, functional foods and supplements for the fundamental treatment of eye diseases and neurological diseases such as cataracts, glaucoma and retinal detachment.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012197729A JP6077243B2 (en) | 2012-09-07 | 2012-09-07 | Differentiation inducer from stem cells to ectoderm cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012197729A JP6077243B2 (en) | 2012-09-07 | 2012-09-07 | Differentiation inducer from stem cells to ectoderm cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014050356A JP2014050356A (en) | 2014-03-20 |
JP6077243B2 true JP6077243B2 (en) | 2017-02-08 |
Family
ID=50609477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012197729A Active JP6077243B2 (en) | 2012-09-07 | 2012-09-07 | Differentiation inducer from stem cells to ectoderm cells |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6077243B2 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4343150B2 (en) * | 2005-06-30 | 2009-10-14 | 太陽化学株式会社 | Theanine production method |
JP2008212136A (en) * | 2006-06-20 | 2008-09-18 | Ikeda Shokken Kk | Post-fermented tea and method for producing the same |
AU2006346492A1 (en) * | 2006-07-24 | 2008-01-31 | International Stem Cell Corporation | Synthetic cornea from retinal stem cells |
JP2008169143A (en) * | 2007-01-11 | 2008-07-24 | Ito En Ltd | Theanine-containing neurocyte new formation-promoting composition and food or drink |
KR20100122296A (en) * | 2009-05-12 | 2010-11-22 | (주)아모레퍼시픽 | Composition containing fermentation tea for improving blood circulation and pharmaceutical composition and health food composition comprising thereof |
-
2012
- 2012-09-07 JP JP2012197729A patent/JP6077243B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014050356A (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6129418B2 (en) | A composition for preventing and treating liver fibrosis or cirrhosis containing mesenchymal stem cells derived from human embryonic stem cells as an active ingredient | |
JP6977051B2 (en) | Cell lines that constantly secrete and express HLA-G protein and methods for producing them | |
JP2022533277A (en) | Composition for promoting stem cell-derived exosome production and enhancing stem cell ability | |
JP6535505B2 (en) | An agent for maintaining undifferentiated state of stem cells and an agent for promoting proliferation using the extract of Mannengtake mushroom | |
JP6583679B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter using yeast extract | |
KR101427102B1 (en) | A Productive method of Zygotic Embryo-derived Embryogenic Cell Suspension Cultures of Camellia sinensis | |
JP5819209B2 (en) | Differentiation promoter from stem cells to brown adipocytes | |
JP6077243B2 (en) | Differentiation inducer from stem cells to ectoderm cells | |
JP6082221B2 (en) | Differentiation inducer from stem cells to ectoderm cells | |
JP6050033B2 (en) | Differentiation inducer from stem cells to ectoderm cells | |
JP6697252B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
CN112368370A (en) | Mesenchymal stem cell and neuropathy therapeutic agent | |
JP6076624B2 (en) | Differentiation inducer from stem cells to mesoderm cells, endoderm cells or mesendoderm cells | |
JP6571494B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter using Ainu Wakame | |
JP6411778B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP6468895B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
KR101862548B1 (en) | composition for inducing differentiation of multi-potent neural stem cell into dopaminergic meurons and method for inducing differentiation using the same | |
JP6649050B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP6587899B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP7202610B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP7214191B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP2019094268A (en) | Undifferentiated state maintenance agent for hair follicle stem cells | |
JP7178087B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP7287653B2 (en) | Proliferation promoter for stem cells | |
JP2018030787A (en) | Agent for maintaining the undifferentiated state of stem cell and agent for promoting the proliferation of stem cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6077243 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |